DaVita delivers consistent earnings beats and strong cash generation, but the stock has moved above analyst consensus targets and carries concentrated exposure to government reimbursement programs representing roughly two-thirds of revenue; the setup favors waiting for a pullback that restores a more favorable entry.
Thesis pillars
- Government Program Revenue Concentration→Stable
- Earnings Beat Streak With Rising Estimates→Stable
- Stock Above Analyst Consensus Target→Stable
- +1 more pillar — see the Why tab for full reasoning
DaVita Inc. (DVA) Stock Analysis
Healthcare · Medical Care Facilities
Sell if holding. At $236.89, A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: Medicare and Medicare Advantage plans (57.0%); Concentration risk — Customer: total government-based programs (68.0%).
DaVita provides kidney dialysis through 2,657 U.S. outpatient centers in 46 states and 585 international centers in 14 countries, serving approximately 200,500 U.S. and 94,500 international patients. U.S. dialysis represents approximately 86% of consolidated revenues; government... Read more
Sell if holding. At $236.89, A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: Medicare and Medicare Advantage plans (57.0%); Concentration risk — Customer: total government-based programs (68.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, no SEC red flags, news events none recent, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: moderate.
Recent developments
updated 2026-07-07Recent Developments — DaVita Inc.
Latest news
- NEWS Here's why you should retain DaVita stock in your portfolio for now - MSN — MSN positive
- NEWS How Analyst Model Shifts Are Rewriting The DaVita (DVA) Investment Narrative - Yahoo Finance — Yahoo Finance neutral
- NEWS Why DaVita HealthCare (DVA) is a top value stock for the long term - MSN — MSN positive
- NEWS DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note - Yahoo Finance — Yahoo Finance positive
- NEWS DaVita Stock Benefits From Expanding Community-Based Kidney Care - TradingView — TradingView positive
Generated 2026-07-07T16:12:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerMedicare and Medicare Advantage plans57%10-K Item 1: 'Medicare and Medicare Advantage plans| 57 | %'
- HIGHCustomertotal government-based programs68%10-K Item 1: 'Total government-based programs| 68 | %'
- MEDIUMCustomercommercial payors32%10-K Item 1: 'The payments we receive from commercial payors generate nearly all of our profits and all of our non-hospital dialysis profits come from commercial payors'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $236.89, A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: Medicare and Medicare Advantage plans (57.0%); Concentration risk — Customer: total government-based programs (68.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $225.14. Score 5.5/10, moderate confidence.
Take-profit target: $234.85 (-1.0% upside). Prior stop was $225.14. Stop-loss: $225.14.
Concentration risk — Customer: Medicare and Medicare Advantage plans (57.0%); Concentration risk — Customer: total government-based programs (68.0%); Analyst target reached - limited upside remaining.
DaVita Inc. trades at a P/E of 22.6 (forward 13.7). TrendMatrix value score: 6.8/10. Verdict: Sell.
13 analysts cover DVA with a consensus score of 3.5/5. Average price target: $194.
What does DaVita Inc. do?DaVita provides kidney dialysis through 2,657 U.S. outpatient centers in 46 states and 585 international centers in 14...
DaVita provides kidney dialysis through 2,657 U.S. outpatient centers in 46 states and 585 international centers in 14 countries, serving approximately 200,500 U.S. and 94,500 international patients. U.S. dialysis represents approximately 86% of consolidated revenues; government programs cover 68% of U.S. dialysis revenues, while commercial payors at 32% generate nearly all profits.